Co-Diagnostics (NASDAQ: CODX) announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has signed an agreement to expand its commercial and distribution territory across South Asia to include Bangladesh, Pakistan, Nepal and Sri Lanka, significantly increasing its addressable market to an estimated $13.0 billion. The expansion supports planned commercialization of the CoSara PCR Pro(R) point-of-care platform and SARAGENE(R) product line, subject to regulatory approvals, as the company builds regional distribution channels and positions for broader deployment of its molecular diagnostics solutions.
This move marks a strategic expansion for Co-Diagnostics, which through CoSara aims to address the growing demand for affordable and accessible molecular diagnostics in South Asia. The region faces significant healthcare challenges, including a high burden of infectious diseases such as tuberculosis, hepatitis, and vector-borne illnesses. By expanding into these four additional countries, CoSara can leverage its proprietary technology to provide rapid and accurate testing solutions that can improve disease surveillance and patient outcomes.
The addressable market estimate of $13 billion reflects the potential for molecular diagnostics across the expanded territory. The CoSara PCR Pro platform, designed for point-of-care use, could be particularly impactful in rural and underserved areas where laboratory infrastructure is limited. Similarly, the SARAGENE product line offers a range of diagnostic tests that can be deployed in various settings. However, commercialization is subject to obtaining necessary regulatory approvals in each country, which may involve varying timelines and requirements.
Co-Diagnostics, a Utah corporation, develops and manufactures molecular diagnostics technologies that detect nucleic acid molecules. The company's proprietary technology is also used for its Co-Dx PCR at-home and point-of-care platform, which is currently under regulatory review and not yet for sale. The expansion of CoSara's territory aligns with the company's broader strategy to increase its global footprint and make its diagnostics more widely available.
For more information about Co-Diagnostics, visit https://co-dx.com/. The full press release is available at https://ibn.fm/2aATV.
Forward-looking statements in this release involve risks and uncertainties, including those detailed in the company's filings with the SEC. The company undertakes no duty to update this information unless required by law.
